Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Heron Therapeutics (HRTX) Net Income towards Common Stockholders: 2010-2025

Historic Net Income towards Common Stockholders for Heron Therapeutics (HRTX) over the last 12 years, with Sep 2025 value amounting to -$4.1 million.

  • Heron Therapeutics' Net Income towards Common Stockholders rose 8.19% to -$4.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year increase of 106.16%. This contributed to the annual value of -$14.0 million for FY2024, which is 87.39% up from last year.
  • Per Heron Therapeutics' latest filing, its Net Income towards Common Stockholders stood at -$4.1 million for Q3 2025, which was down 150.03% from -$1.6 million recorded in Q2 2025.
  • In the past 5 years, Heron Therapeutics' Net Income towards Common Stockholders ranged from a high of $4.2 million in Q4 2024 and a low of -$62.9 million during Q1 2022.
  • For the 3-year period, Heron Therapeutics' Net Income towards Common Stockholders averaged around -$11.3 million, with its median value being -$4.8 million (2024).
  • As far as peak fluctuations go, Heron Therapeutics' Net Income towards Common Stockholders fell by 20.74% in 2022, and later skyrocketed by 165.74% in 2025.
  • Quarterly analysis of 5 years shows Heron Therapeutics' Net Income towards Common Stockholders stood at -$53.5 million in 2021, then surged by 61.98% to -$20.4 million in 2022, then soared by 49.79% to -$10.2 million in 2023, then spiked by 140.83% to $4.2 million in 2024, then increased by 8.19% to -$4.1 million in 2025.
  • Its Net Income towards Common Stockholders was -$4.1 million in Q3 2025, compared to -$1.6 million in Q2 2025 and $3.2 million in Q1 2025.